Extensively Drug-resistant Tuberculosis (XDR-TB)-inhibitors to Overcome the Scourge of Drug-resistant Tuberculosis: a Perspective

TB is the 9th leading cause of death worldwide above HIV/AIDS. Tuberculosis (TB) management remains challenging due to the emergence of drug-resistant tuberculosis such as MDR-TB and XDR-TB. To improvise therapeutic results for MDR/XDR-TB, 89 nations had started utilizing bedaquiline and 54 had utilized delamanid by June 2017. Unfortunately, cardiac arrhythmia was found to be the most serious side effect associated with the both drugs restricting their use for the management of MDR- and XDR-TB. The current review discussed the clinically trialed and approved drug for the treatment of XDR-TB, recently reported compounds against XDR-TB, their synthesis and activity spectrum. This information could be helpful to the medicinal chemist in synthesizing the best XDR-TB inhibitors free from resistance and toxicity.